絞り込み

16260

広告

Red Marrow Absorbed Dose for non-Hodgkin's Lymphoma Patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan.

著者 Blakkisrud J , Løndalen A , Dahle J , Turner S , Holte H , Kolstad A , Stokke C
J Nucl Med.2016 Sep 1 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (8view , 0users)
  • このエントリーをはてなブックマークに追加

Full Text Sources

Miscellaneous

Red bone marrow (RM) is often the primary organ at risk in radioimmunotherapy; irradiation of marrow may induce short and long term hematological toxicity. (177)Lu-lilotomab satetraxetan is a novel anti-CD37 antibody-radionuclide-conjugate (ARC) currently in phase 1/2a. Two pre-dosing regimens have been investigated, one with 40 mg unlabeled lilotomab antibody (arm 1) and one without (arm 2). The aim of this work was to compare RM absorbed doses for the two arms and to correlate absorbed doses with hematological toxicity.
PMID: 27587710 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード